Find Academic Supervisors

Brian R. Smith is Professor of Laboratory Medicine, Biomedical Engineering, Internal Medicine (Hematology) and Pediatrics at Yale University. He serves as Deputy Dean for Clinical and Translational Research at the Yale School of Medicine, Co-Director of the Yale Center for Clinical Investigation, and Chair of the Department of Laboratory Medicine. Dr. Smith is also Chief of Laboratory Medicine and Attending Physician at Yale New Haven Hospital, as well as an attending physician at the Connecticut VA Medical Center and Bridgeport Hospital. Dr. Smith's research focuses on the inflammation-hemostasis interface, particularly in relation to biomaterials, and cellular immunotherapeutics. His work spans the full translational spectrum from basic wet bench research through clinical and epidemiological trials (T1-T4). He has been continuously funded by the NIH at the PI-level for over 35 years, demonstrating sustained excellence in translational research. His investigations have particular emphasis on hematologic malignancies, diagnostic accuracy, and the educational frameworks needed to train future laboratory medicine specialists. Analysis of Dr. Smith's publications reveals a consistent focus on advancing laboratory medicine through both clinical research and educational innovation. His work addresses critical issues in diagnostic accuracy, physician-scientist training pathways, and the integration of new technologies into clinical practice. The publications span oncology, hematology, medical education, and healthcare systems, reflecting his interdisciplinary approach to advancing laboratory medicine. Evans Award for Outstanding Contributions to Laboratory Medicine (2010) President, Academy of Clinical Laboratory Physicians & Scientists (2007-2008) Chair (elected), Research Committee and Member of the Council, Association of Pathology Chairs (2010) Dr. Smith has been instrumental in developing Yale's research infrastructure, overseeing implementation of research core facilities in Translational Immune Monitoring, Flow Cytometry, and Clinical Sample Real Time Acquisition. He chairs the Clinical Research Technology Committee and has guided the development of a Cellular Therapy core resource. As an educator, he has personally mentored over 50 MD, MD/PhD, and PhD trainees, most of whom hold tenure-track positions. He is the initiator and long-standing PI of Laboratory Medicine's post-doctoral T32 training program in Immunohematology. Dr. Smith has played a key national role in laboratory medicine education, developing curricula and physician-scientist training paradigms. Through his leadership in the Association of Pathology Chairs, he helped establish a specific Physician-Scientist residency pathway with the American Board of Pathology, addressing a critical need for specialized training in academic pathology.

• inflammation-hemostasis interface
• biomaterials
• cellular immunotherapeutics
• +7 more

Steven M. Dubinett is a distinguished academic leader at the University of California Los Angeles (UCLA), serving as Dean of the School of Medicine and holding professorships in Medicine, Pathology and Laboratory Medicine, and Molecular and Medical Pharmacology. His work is deeply integrated with key research centers including the UCLA Jonsson Comprehensive Cancer Center and the UCLA Clinical and Translational Science Institute, where he drives innovation in lung cancer research and translational medicine. Dubinett earned his medical degree from Rutgers New Jersey Medical School in 1980, followed by an internship and residency in Internal Medicine at University Hospital and UCLA. He completed specialized fellowships in Pulmonary Medicine at Massachusetts General Hospital and in Tumor Immunology at Harvard Medical School, establishing the foundation for his career at the intersection of pulmonary medicine and cancer research. Dr. Dubinett's research program is centered on the pathogenesis of lung cancer, with particular emphasis on translational approaches to understanding immunobiology, tumor microenvironment dynamics, and mechanisms of epithelial-mesenchymal transition in human non-small cell lung cancer. His laboratory has made seminal contributions to understanding how chronic inflammation drives lung carcinogenesis and how these insights can be translated into novel therapeutic strategies. His work bridges molecular mechanisms with clinical applications, focusing on identifying targets for lung cancer interception and prevention. Analysis of Dr. Dubinett's recent publications (2023-2025) reveals a sophisticated integration of multi-omics approaches with spatial analysis to understand lung adenocarcinoma evolution. His research increasingly focuses on tumor heterogeneity, immune microenvironment characterization, and innovative immunotherapeutic approaches including dendritic cell vaccines and engineered immune cells. A significant portion of his work addresses mechanisms of immunotherapy resistance and strategies to overcome it through combination approaches. Among his numerous accolades, Dr. Dubinett received the prestigious William S. Middleton Award from the U.S. Department of Veterans Affairs in 2019, the American Thoracic Society Recognition Award for Scientific Accomplishments in 2008, and the Stanley Blatt Award for Lung Cancer Research in 1999. His work has been consistently recognized by the American Lung Association through multiple awards spanning his career. Dr. Dubinett has secured substantial research funding throughout his career, including NIH grants and institutional support that has enabled his team to pursue cutting-edge approaches to lung cancer diagnosis and treatment. His leadership extends to national advisory roles, including chairing the FDA Cellular, Tissue and Gene Therapies Advisory Committee, and representing UCLA in international research collaborations with the Chinese Academy of Sciences. He has mentored numerous physician-scientists who have gone on to establish their own research programs in oncology and pulmonary medicine. Dr. Dubinett leads a multidisciplinary research team within the UCLA Jonsson Comprehensive Cancer Center focused on translating basic discoveries into clinical applications. His laboratory employs advanced techniques in molecular biology, immunology, and systems biology to investigate the molecular mechanisms of lung cancer development and progression. Current research directions include developing non-invasive diagnostic approaches using liquid biopsies, understanding the evolution of premalignant lesions, and developing novel immunotherapeutic strategies to enhance T-cell responses against lung cancer.

• Lung Cancer Research
• Translational Medicine
• Immunobiology
• +5 more

Stanley Riddell, M.D., is a Professor at the University of Washington School of Medicine's Department of Immunology and holds the Burke O’Reilly Family Endowed Chair in Immunotherapy at Fred Hutchinson Cancer Research Center. He leads the Riddell Lab, focusing on adoptive T-cell therapy, CAR T-cell engineering, and overcoming tumor immune evasion. His work includes clinical trials targeting B-cell malignancies, solid tumors, and viral infections post-transplant. Key contributions include CD19 CAR T-cell therapy for leukemia/lymphoma and identification of tumor antigens like BRAFV600E. He collaborates with institutions like TUM School of Medicine and UW's Institute for Protein Design. Education: MD from University of Manitoba (1979), residency/internal medicine (1983), hematology fellowship (1985). Clinical expertise includes stem cell transplantation and GVHD management. Awards include the American Cancer Society Research Professorship. His lab includes researchers like Josh Veatch, Carla Jaeger, and postdocs Tamer Shabaneh/Sylvain Simon. Research spans immunotherapy safety, T-cell subset optimization, and neoantigen targeting. Current projects address solid tumor CAR T-cell challenges, ROR1-targeted therapies, and synthetic biology innovations.

• Cancer Immunology
• Adaptive Immune Responses
• CAR T-cell Therapy
• +3 more

Angelo Porciuncula is an Associate Research Scientist in the Department of Pathology at Yale School of Medicine, affiliated with the Schalper Lab. He holds a PhD from the University of Navarra. His research focuses on immunology, cancer therapy, and stem cell biology, with a particular emphasis on immune microenvironment modulation in oncology and translational drug development. Key projects include studying STING pathway activation via antibody-drug conjugates (e.g., TAK-500) targeting CCR2-expressing myeloid cells, as well as investigating immunotherapeutic biomarkers in lung cancer and glioblastoma. His work spans clinical-stage drug evaluation, tumor immunology, and epigenetic reprogramming of stem cells. Publications highlight contributions to understanding senescence mechanisms in cancer, pancreatic differentiation of iPSCs, and the role of OX40/OX40L pathways in tumor immunity. Porciuncula collaborates widely, including with Kurt Schalper and teams at Takeda Pharmaceuticals. His research bridges basic science and clinical applications, aiming to advance targeted therapies and regenerative medicine strategies.

• Immunology
• Cancer Therapy
• Oncology
• +3 more

Margaret E Ackerman serves as Professor of Microbiology and Immunology at Dartmouth's Geisel School of Medicine and holds a joint appointment as Professor of Engineering at Thayer School of Engineering. Her office is located in Cummings Hall (119B) at 14 Engineering Drive, Hanover, NH. Dr. Ackerman's research program focuses on applying molecular engineering tools and quantitative analysis to develop immunotherapeutics and vaccines. Her laboratory specializes in parsing humoral immune responses to vaccination and infection, developing quantitative understanding of antibody functions, and creating platforms for combinatorial display and in vitro evolution of candidate vaccine immunogens. This interdisciplinary work bridges fundamental immunology with protein engineering approaches to address critical challenges in vaccine design and therapeutic antibody development. Her laboratory maintains an active research program with numerous graduate students and postdoctoral researchers working on projects related to HIV and cancer therapeutics. Current team members include PhD candidates in the Molecular and Cellular Biology program and co-advised students working with colleagues in Microbiology, Immunology, and Computer Science departments. Dr. Ackerman maintains her research laboratory website (ackermanlab.org) which details ongoing projects, team members, and publications. She can be reached at Margaret.E.Ackerman@Dartmouth.edu or by phone at 603-646-9922.

• Immunology
• Vaccine Development
• Antibody Engineering
• +4 more

Jeffrey Wolf, MD, is a Professor in the Department of Medicine at the University of California, San Francisco (UCSF), School of Medicine. He serves as the Director of the Myeloma Program, where he leads clinical and translational research focused on multiple myeloma and plasma cell disorders. His work emphasizes novel immunotherapies, including CAR-T cells, bispecific antibodies, and targeted agents, with a strong commitment to improving patient outcomes through clinical trials. Dr. Wolf’s research interests center on advancing therapeutic strategies for multiple myeloma, particularly BCMA, GPRC5D, CD38, and CD70-targeted therapies. His laboratory and clinical studies explore mechanisms of treatment resistance, T-cell exhaustion, immune-related toxicities, and the myeloma surfaceome to identify new targets. He actively investigates the interplay between immunotherapy and host immunity, including vaccine responses in immunocompromised patients. His work spans from basic molecular mechanisms to phase 1 and 2 clinical trials, reflecting a robust translational approach. The 15 most recent publications highlight a consistent focus on immunotherapeutic advances in multiple myeloma. Key themes include CAR-T cell therapy (BCMA, CD70), mechanisms of resistance and toxicity (e.g., T-cell exhaustion, enterocolitis, MAS-L), and novel antibody-based approaches (e.g., targeting GPRC5D, CD38). There is a strong emphasis on clinical translation, with multiple phase 1b and observational studies informing treatment optimization and patient management strategies. Director, Myeloma Program, UCSF Professor, Department of Medicine, UCSF School of Medicine Active principal or co-investigator on numerous clinical trials in multiple myeloma Extensive collaborations with leaders in hematology-oncology including Thomas Martin, Nina Shah, and Arun Wiita Dr. Wolf has mentored numerous researchers and clinicians through his role at UCSF and has contributed to the training of hematologists and oncologists. While specific advisees are not listed in the provided text, his extensive co-authorship network suggests a strong commitment to collaborative science and academic mentorship. He has not received any explicitly listed scientific awards in the provided data, but his publication record in top-tier journals and leadership in clinical trials indicate significant recognition in the field. His work is conducted within the UCSF Myeloma Program, a multidisciplinary team dedicated to research and treatment of plasma cell disorders. The program engages in cutting-edge translational research, clinical trial development, and patient care, with a focus on immunotherapy and personalized medicine approaches.

• Multiple Myeloma
• Hematology
• Oncology
• +13 more

David A. Scheinberg is a Professor at Memorial Sloan Kettering Cancer Center , Chair of the Center for Experimental Therapeutics, and Deputy Director of the Sloan Kettering Institute for Therapeutic Discovery. He is affiliated with the Molecular Pharmacology Program, Department of Medicine, and the Tri-Institutional PhD Program in Chemical Biology. BA, Cornell University MD and PhD, Johns Hopkins University School of Medicine Internal Medicine Residency, New York Hospital Dr. Scheinberg pioneers targeted immunotherapies using antibodies, TCR mimicry, CAR T cells, and nanodevices. His work bridges translational medicine and cancer pharmacology , focusing on intracellular oncogenic proteins like WT1. Key innovations include TCR-like antibodies (2013-2015) and cellular micropharmacies (2021), advancing into clinical trials for leukemia and solid tumors. His recent publications highlight WT1 as a universal cancer target , bispecific T-cell engagers , and nanoscale drug delivery systems . These studies span Antibody-dependent cytotoxicity Tumor antigen specificity HLA-restricted immune responses Nano-machine activation Clinical trial translation Scientific accolades include Nature Biotech Top 15 Translational Scientists Doris Duke Distinguished Clinical Scientist Emil Freireich Prize Membership in elite societies: American Association of Physicians, American Society for Clinical Investigation, Interurban Clinical Club As a mentor, Dr. Scheinberg has advised over 25 graduate students and postdoctoral researchers. His lab collaborates with the Geoffrey Beene Cancer Research Center and Center for Cell Engineering , supported by NIH grants (R01 CA055349, P01 CA023766, UL1 TR000457).

• Cancer Immunotherapy
• Molecular Pharmacology
• Drug Discovery
• +3 more

Andrew B. Ward is a Professor in the Department of Integrative Structural and Computational Biology at The Scripps Research Institute. His research focuses on membrane proteins and viruses, employing integrative structural biology techniques such as x-ray crystallography and electron microscopy. He investigates viral entry mechanisms and antibody-mediated neutralization, with a particular emphasis on HIV, influenza, and other pathogens. Ward’s work aims to design better vaccines by understanding antibody-virus interactions and structural dynamics. Education: Ph.D., The Scripps Research Institute, 2008 B.S., Duke University, 2001 Research Interests: Membrane protein transporters Viral entry mechanisms Structural basis of antibody neutralization Design of broadly neutralizing antibodies Influenza and HIV vaccine development Scientific Awards: Young Investigator in Virology Award (2017) Anne Palmenberg Junior Investigator Award (2014) Ray Thomas Edwards Foundation Fellowship (2013) Advising & Grants: Ward’s lab has contributed to numerous collaborative projects on viral structures and vaccine design. Grants include funding from NIH and the National Science Foundation. His lab’s work frequently involves structural biology and computational modeling to advance immunotherapeutic strategies. Labs/Teams: His laboratory focuses on structural virology and antibody engineering, collaborating with institutes globally to combat infectious diseases.

• Structural Biology
• Virology
• Membrane Proteins
• +3 more

Sihong Wang serves as an Associate Professor within the Department of Biomedical Engineering at the City College of New York (CCNY), part of the City University of New York system. His research laboratory is housed in Steinman Hall (Room 434), where he develops advanced microfluidic platforms for biomedical applications. Dr. Wang maintains active research collaborations across engineering and life science disciplines, with contact facilitated through shwang@ccny.cuny.edu and phone 212-650-5189. Dr. Wang's research program centers on innovative microfluidic technologies that model complex biological systems with clinical relevance. His work bridges engineering precision with biological inquiry to create dynamic in vitro platforms for tumor microenvironment simulation, immune cell interaction studies, and stem cell differentiation analysis. Key focus areas include thermal modulation of cellular responses, high-throughput drug screening systems, and CRISPR-based validation of therapeutic mechanisms. This research directly impacts cancer immunotherapy development, regenerative medicine strategies, and pharmacological testing paradigms through engineered microenvironments that recapitulate physiological conditions. Analysis of Dr. Wang's publication trajectory (2013-2024) reveals an escalating sophistication in microfluidic platform design, evolving from foundational heat shock protein kinetics studies toward integrated systems for immune cell recirculation and tumor-stroma interaction modeling. His recent work demonstrates consistent innovation in creating dynamic, physiologically relevant microenvironments that capture temporal cellular responses—particularly evident in 2022-2024 immunotherapy-focused publications. The research consistently applies engineering principles to solve biological challenges, with increasing emphasis on clinical translation of microfluidic technologies for cancer treatment assessment. No scientific awards, graduate student mentorship records, research grant details, or laboratory infrastructure descriptions were documented in the source materials. Similarly, information regarding collaborative teams, future research directions, or educational background remains undisclosed in the available information.

• Biomedical Engineering
• Microfluidics
• Tissue Engineering
• +3 more

Ryan O'Connell is a Professor in the Department of Pathology at the University of Utah and Chief of Microbiology and Immunology. His research laboratory is located at the Huntsman Cancer Institute. He also serves as Co-Director of the Immunology, Inflammation and Infectious Disease (3i) Initiative, Associate Chief of the Microbiology and Immunology Division, and Program Co-Director of the Neuroimmunology Training Grant. Education: B.S. California Lutheran University Ph.D. University of California, Los Angeles Research Interests: Dr. O'Connell's research focuses on the roles of microRNAs (miRNAs) in regulating both physiological and pathological immune cell functions in mammals, with an emphasis on inflammation and cancer. His laboratory is currently investigating: Communication between the mammalian host and gut microbiota via extracellular vesicles and their RNA cargo during inflammatory bowel disease (IBD) and colorectal cancer (CRC) The role of miRNAs in coordinating antitumor and immunotherapeutic responses to gastrointestinal (GI) and blood cancers Development and mechanistic study of mRNA vaccines to induce immunity against GI and blood cancers Interplay between miRNAs and cellular metabolism during age-related inflammation and cancer Publications: Dr. O'Connell has published over 100 high-impact primary research manuscripts and review articles. His recent work spans diverse areas including cancer immunotherapy, microbiota interactions, metabolic regulation in immune cells, and the development of bioinformatics tools for cancer genomics. Leadership and Mentorship: He has mentored 14 graduate students (including 4 MD/PhD students) and 6 postdoctoral scholars, many of whom have advanced to positions in academia and industry. His leadership roles include directing major initiatives in immunology and inflammation research at the University of Utah.

• Noncoding RNAs
• Inflammation
• Cancer
• +3 more

Valentina Hoyos, M.D., is an Associate Professor at Baylor College of Medicine, affiliated with the Center for Cell and Gene Therapy and the Lester and Sue Smith Breast Center. She holds a Medical Degree (MD) from Javeriana University (2006) and completed a Postdoctoral Fellowship at Baylor College of Medicine (2009). Her clinical focus is on breast cancer treatment, while her research emphasizes improving cellular immunotherapies, particularly T cell therapies targeting tumor-specific antigens and overcoming tumor microenvironment challenges. Key interests include CAR T cell engineering, TRAIL receptor targeting, and personalized therapies for metastatic breast cancer. Education: MD, Javeriana University (2006) Postdoctoral Fellowship, Baylor College of Medicine (2009) Residency in Internal Medicine (MeRIT Scholar), Baylor College of Medicine (2014) Clinical Fellowship in Oncology, Johns Hopkins University (2017) Research Interests: Dr. Hoyos is advancing cellular immunotherapies to combat cancer, particularly breast cancer. Her work includes engineering T cells to target tumor-specific antigens like ESR1 mutations and optimizing CAR T cell efficacy by addressing immunosuppressive elements in the tumor microenvironment. She investigates strategies to enhance T cell infiltration and persistence using genes like heparanase and TRAIL receptors. Grants & Awards: CPRIT Scholar (2017–2022) Susan G. Komen Career Catalyst Research Grant (2019–2022) Advising & Grants: Her research is supported by grants focused on breast cancer therapies and TCR-engineered T cells. She collaborates on clinical trials integrating immunotherapy with checkpoint inhibitors and explores novel targets like ZP4 for triple-negative breast cancer. Labs/Teams: Active in Baylor's Center for Cell and Gene Therapy and the Lester and Sue Smith Breast Center, she leads multidisciplinary teams advancing cell therapy and precision oncology.

• Cellular Immunotherapy
• Cancer Treatment
• Immunotherapy
• +3 more

Dr. Rakez Kayed is a Professor in the Department of Neurology at the University of Texas Medical Branch (UTMB) and holds the John Sealy Chair for Parkinson's Research. He leads research at the Mitchell Center for Neurodegenerative Disorders, focusing on molecular mechanisms of neurodegenerative diseases including Alzheimer's, Parkinson's, and tauopathies. His work investigates protein misfolding, tau oligomer toxicity, and immunotherapeutic approaches. Education: B.S. Chemistry, University of Jordan Ph.D. in Organic/Medicinal Chemistry, University of Tübingen Postdoctoral training in Alzheimer's and Protein Misfolding Diseases, University of California, Irvine Dr. Kayed's research explores neurodegenerative pathology, protein aggregation dynamics, and therapeutic targeting of amyloid and tau oligomers. His lab develops diagnostic biomarkers using biological samples and studies amyloid involvement in cancer, diabetes, and traumatic brain injury. Recent work emphasizes immunotherapeutic strategies to halt disease progression. His publications frequently address tau pathology propagation, oligomer toxicity, and neuroinflammation mechanisms. Articles show consistent focus on bridging basic protein biochemistry with clinical applications in neurodegeneration. Awards: Warmoth Professorship in Neurology International Society for Neurochemistry Fellowship Society for Neuroscience Award DFG Fellowship Dr. Kayed collaborates internationally and contributes to editorial boards of major neurology journals. His lab employs molecular biology, animal models, and translational approaches to advance neurodegenerative disease therapeutics.

• Neurodegenerative Diseases
• Protein Misfolding
• Tau Oligomer Toxicity
• +4 more

Henrique Borges da Silva, Ph.D., is an Assistant Professor of Immunology at Mayo Clinic in Phoenix, Arizona. He holds dual appointments in the Department of Research and the Department of Cancer Biology, where he leads a research laboratory focused on understanding how extracellular nucleotides regulate CD8-positive T cell immunity in infections and cancer. University: Mayo Clinic School: Department of Research Department: Department of Cancer Biology Academic Rank: Assistant Professor Dr. Borges da Silva earned his Ph.D. in Immunology from the University of Sao Paulo, Brazil, followed by postdoctoral training at the University of Minnesota and the University of Sao Paulo. His research centers on purinergic signaling, particularly the role of the P2RX7 receptor in shaping T cell memory, metabolism, and function. He investigates how extracellular ATP influences transcriptional and metabolic pathways in CD8+ T cells during immune responses, aiming to improve vaccines and immunotherapies. His recent publications reveal a strong trend in understanding the metabolic fitness of memory T cells, the sources and sensing of extracellular ATP in vivo, and the broader roles of purinergic signaling in adaptive immunity. His work spans fundamental immunology, cancer immunotherapy, and infectious disease, with high-impact studies in journals such as Nature , Immunity , and Science Immunology . K99/R00 Career Development Grant, NIH/NIAID (AI139381), 2019–present Associate Membership, Sigma Xi, 2019 Honorable Mention, Best Ph.D. Thesis, University of Sao Paulo, 2015 Dr. Borges da Silva actively mentors students and collaborates on projects involving T cell biology, immunometabolism, and purinergic signaling. His lab employs cutting-edge tools including CRISPR-Cas9, shRNA screening, and in vivo ATP sensing systems. He has contributed to understanding T cell responses in malaria, viral infections, and solid tumors, and his work has implications for developing novel immunotherapeutic strategies. His laboratory is actively involved in studying tissue-resident memory T cells, metabolic reprogramming, and the role of ion channels and purinergic receptors in immune regulation. Collaborations span immunology, oncology, and infectious disease research, contributing to Mayo Clinic's comprehensive cancer and immunology programs.

• Immunology
• T Cell Biology
• Immunometabolism
• +9 more

Venuprasad Poojary, Ph.D., is an Associate Professor in the Departments of Internal Medicine and Immunology at UT Southwestern Medical Center and a member of the Division of Digestive and Liver Diseases. He joined the faculty in 2019. His research focuses on regulatory mechanisms of immune cells in gastrointestinal inflammation and cancer, with a goal to identify therapeutic targets for chronic inflammatory diseases. Education: B.Sc. in Biochemistry (Mangalore University), M.Sc. in Bioscience (Mangalore University), Ph.D. in Immunology (National Center for Cell Science, Kolkata). Postdoctoral training at La Jolla Institute for Allergy and Immunology (San Diego). Research interests include Th17 cell regulation, RORγt signaling, mitochondrial dysfunction in inflammation, and immunotherapeutic approaches for intestinal disorders. His lab investigates mechanisms linking inflammation to cancer and autoimmune conditions, with recent work on protein modifications and mitochondrial pathways. Publications span topics like colonic inflammation, T-cell exhaustion, and Wnt/β-catenin inhibition, emphasizing translational research. He is affiliated with professional organizations including the American Association of Immunologists and American Association for Cancer Research. Led by Dr. Poojary, the Poojary Research Lab collaborates on projects addressing immune checkpoints and therapeutic development. No specific grants or advisees are listed, but the lab actively engages in collaborative research initiatives.

• Immunology
• Gastrointestinal Disorders
• Inflammation Regulation
• +3 more

Yi Lin, M.D., Ph.D., is a Professor of Medicine and Assistant Professor of Oncology at Mayo Clinic, with primary and joint appointments in the Department of Internal Medicine, Division of Hematology, and the Department of Laboratory Medicine and Pathology, Division of Experimental Pathology and Laboratory Medicine. She is the Enterprise Leader for Cancer Regenerative Medicine, Biotherapeutics, and Biomanufacturing at the Mayo Clinic Comprehensive Cancer Center, Rochester, Minnesota. Education: BS in Chemical Engineering, University of Minnesota Ph.D. in Biomedical Engineering, University of Minnesota MD, Northwestern University Feinberg School of Medicine Residency and Fellowship, Mayo Clinic College of Medicine Dr. Lin is a hematologist and oncologist specializing in lymphoma, multiple myeloma, and cell therapy. Her research is centered on cancer immunotherapy, with a focus on CAR T-cell therapies, cancer vaccines, biomarkers of response and toxicity, and bioprinted tumor models. Her work has directly contributed to FDA approvals of CAR-T therapies such as Yescarta, Abecma, and Carvykti. She employs gene-editing tools and translational research to improve the safety and efficacy of next-generation immunotherapies. Analysis of her recent publications reveals a strong emphasis on clinical and translational immunotherapy, particularly in hematologic malignancies. Her work spans clinical outcomes in CAR-T therapy, biomarker discovery, resistance mechanisms involving myeloid cells, and innovative bioprinting models for drug testing. Her research integrates clinical data with laboratory science to develop personalized, risk-adapted treatment strategies. Scientific Awards: New Investigator Award, Mayo Clinic Department of Medicine (2017) NIH Loan Repayment Program (2012, 2007) AFLAC Scholar-in-training Award, AACR (2008) J. Thomas Livermore Award, University of Minnesota (2001) Merit-based Travel Awards, American Society of Hematology (2000, 1998) Dr. Lin has served as principal investigator on numerous NIH-funded and industry-sponsored clinical trials. She mentors research teams and collaborates nationally and internationally with organizations such as the International Myeloma Working Group, SITC, and BMT CTN. Her leadership roles include chairing the Cell Therapy Cross-Disciplinary Group and co-chairing immunotherapy committees. She is actively involved in developing clinical guidelines and advancing cellular therapy standards. Labs and Teams: Dr. Lin leads a multidisciplinary research team focused on cancer immunology and cellular therapy within the Mayo Clinic Center for Regenerative Medicine and the David F. and Margaret T. Grohne Cancer Immunology and Immunotherapeutics Program. Her lab integrates clinical trial data with translational research to innovate safer and more effective cancer treatments.

• Cancer Immunotherapy
• Cell Therapy
• Hematology
• +12 more